@article{8a9ce5f3d55d4a498808832290ebd4d8,
title = "Defining aggressive prostate cancer using a 12-gene model",
abstract = "The critical clinical question in prostate cancer research is: How do we develop means of distinguishing aggressive disease from indolent disease? Using a combination of proteomic and expression array data, we identified a set of 36 genes with concordant dysregulation of protein products that could be evaluated in situ by quantitative immunohistochemistry. Another five prostate cancer biomarkers were included using linear discriminant analysis, we determined that the optimal model used to predict prostate cancer progression consisted of 12 proteins. Using a separate patient population, transcriptional levels of the 12 genes encoding for these proteins predicted prostate-specific coding antigen failure in 79 men following surgery for clinically localized prostate cancer (P = .0015). This study demonstrates that cross-platform models can lead to predictive models with the possible advantage of being more robust through this selection process.",
keywords = "Bioinformatics, Cancer, Metastasis, Prostate cancer, Proteomics",
author = "Bismar, {Tarek A.} and Francesca Demichelis and Alberto Riva and Robert Kim and Sooryanarayana Varambally and Le He and Jeff Kutok and Aster, {Jonathan C.} and Jeffery Tang and Rainer Kuefer and Hofer, {Matthias D.} and Febbo, {Phillip G.} and Chinnaiyan, {Arul M.} and Rubin, {Mark A.}",
note = "Funding Information: Abbreviations: PSA, prostate-specific antigen; AMACR, alpha-methylacyl CoA racemase; FAS, fatty acid synthase; EZH2, enhancer of Zeste 2; ZAG, zinc alpha-2-glycoprotein; XIAP, X-linked inhibitor of apoptosis; TPD52, tumor protein D 52; KLF6, Kruppel-like factor 6; MTA1, metastasis-associated gene 1 Address all correspondence to: Mark A. Rubin, MD, Brigham and Women{\textquoteright}s Hospital, 75 Francis Street, Boston, MA 02115. E-mail: marubin@partners.org 1This work was supported by SPORE National Cancer Institute (NCI) grants P50CA90381 (M.A.R.), P50CA69568(M.A.R. and A.M.C.), CA 97063 (A.M.C. and M.A.R.), and R01AG21404 (M.A.R.), American Cancer Society grant RSG-02-179-MGO (A.M.C. and M.A.R.), Department of Defense (PC051081 to A.M.C. and S.V.), Early Detection Research Network (U01 CA111275-01 to A.M.C. and M.A.R.), NIH Prostate Specialized Program of Research Excellence (SPORE) (P50CA69568 to A.M.C.), and the UM Cancer Center Support Grant (5P30 CA46592). A.M.C. is a Pew Biomedical Scholar. 2Tarek A. Bismar and Francesca Demichelis contributed equally to this work. 3Drs. Chinnaiyan and Rubin share cosenior authorship. Received 30 September 2005; Revised 2 November 2005; Accepted 3 November 2005.",
year = "2006",
month = jan,
doi = "10.1593/neo.05664",
language = "English (US)",
volume = "8",
pages = "59--68",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "1",
}
